Teva’s generic Viread launches

Press enter to search
Close search
Open Menu

Teva’s generic Viread launches

By David Salazar - 12/15/2017

Tevs has introduced its exclusive generic of Gilead’s Viread (tenofovir disoproxil fumarate), the company announced Friday. The drug is indicated to treat HIVE in adults and pediatric patients ages 2 years old and older, as well as chronic hepatitis B in patients ages 12 years old and older.

“Currently, 1.1 million people in the U.S are living with HIV and an estimated 850,000 to 2.2 million have chronic hepatitis B virus infection,” Teva executive vice president of North America commercial Brendan O’Grady said. “The launch of generic Viread is an important addition to our portfolio; but, more importantly, it brings an effective, affordable treatment option to these patients in an area that’s lacking.”

Teva’s generic will be available in 300-mg dosage strength tablets. The product had U.S. sales of roughly $762 million for the 12 months ended October 2017, according to IQVIA data.


Related Topics